JP6728221B2 - 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン - Google Patents

長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン Download PDF

Info

Publication number
JP6728221B2
JP6728221B2 JP2017552890A JP2017552890A JP6728221B2 JP 6728221 B2 JP6728221 B2 JP 6728221B2 JP 2017552890 A JP2017552890 A JP 2017552890A JP 2017552890 A JP2017552890 A JP 2017552890A JP 6728221 B2 JP6728221 B2 JP 6728221B2
Authority
JP
Japan
Prior art keywords
dose
pp1m
administration
administered
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017552890A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018510894A5 (enExample
JP2018510894A (ja
Inventor
ゴパル，スリハリ
ジェラルダ マリア ラヴェンスティン，ポーリーン
ジェラルダ マリア ラヴェンスティン，ポーリーン
ルッソ，アルベルト
ナライン サムタニ，マヘシュ
ナライン サムタニ，マヘシュ
Original Assignee
ヤンセン ファーマシューティカルズ，インコーポレーテッド
ヤンセン ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57072843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6728221(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ヤンセン ファーマシューティカルズ，インコーポレーテッド, ヤンセン ファーマシューティカルズ，インコーポレーテッド filed Critical ヤンセン ファーマシューティカルズ，インコーポレーテッド
Publication of JP2018510894A publication Critical patent/JP2018510894A/ja
Publication of JP2018510894A5 publication Critical patent/JP2018510894A5/ja
Application granted granted Critical
Publication of JP6728221B2 publication Critical patent/JP6728221B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2017552890A 2015-04-07 2016-03-30 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン Active JP6728221B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562144054P 2015-04-07 2015-04-07
US62/144,054 2015-04-07
US201562162596P 2015-05-15 2015-05-15
US62/162,596 2015-05-15
PCT/US2016/024841 WO2016164218A1 (en) 2015-04-07 2016-03-30 Dosing regimen for missed doses for long-acting injectable paliperidone esters

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019231631A Division JP7228503B2 (ja) 2015-04-07 2019-12-23 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン

Publications (3)

Publication Number Publication Date
JP2018510894A JP2018510894A (ja) 2018-04-19
JP2018510894A5 JP2018510894A5 (enExample) 2019-05-09
JP6728221B2 true JP6728221B2 (ja) 2020-07-22

Family

ID=57072843

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017552890A Active JP6728221B2 (ja) 2015-04-07 2016-03-30 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン
JP2019231631A Active JP7228503B2 (ja) 2015-04-07 2019-12-23 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン
JP2021086909A Active JP7422277B2 (ja) 2015-04-07 2021-05-24 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019231631A Active JP7228503B2 (ja) 2015-04-07 2019-12-23 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン
JP2021086909A Active JP7422277B2 (ja) 2015-04-07 2021-05-24 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン

Country Status (27)

Country Link
US (1) US10143693B2 (enExample)
EP (3) EP3280416B1 (enExample)
JP (3) JP6728221B2 (enExample)
KR (3) KR102755145B1 (enExample)
AU (4) AU2016244801B2 (enExample)
BR (1) BR112017021383A2 (enExample)
CA (2) CA3088401A1 (enExample)
CY (1) CY1123203T1 (enExample)
DK (2) DK3744326T3 (enExample)
EA (1) EA037185B1 (enExample)
ES (2) ES2802299T3 (enExample)
FI (1) FI3744326T3 (enExample)
HR (2) HRP20201027T1 (enExample)
HU (2) HUE065435T2 (enExample)
IL (3) IL254669B2 (enExample)
LT (2) LT3744326T (enExample)
MA (1) MA41917B1 (enExample)
MD (2) MD3280416T2 (enExample)
NZ (1) NZ735952A (enExample)
PL (2) PL3280416T3 (enExample)
PT (2) PT3744326T (enExample)
RS (2) RS65024B1 (enExample)
SI (2) SI3280416T1 (enExample)
SM (2) SMT202000351T1 (enExample)
TW (1) TWI694825B (enExample)
UA (1) UA118732C2 (enExample)
WO (1) WO2016164218A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3744326T3 (da) 2015-04-07 2024-02-05 Janssen Pharmaceutica Nv Doseringsregime for glemte doser til langtidsvirkende injicerbare paliperidonestere
EP3700531B1 (en) 2017-10-27 2025-06-25 Geneora Pharma (Shijiazhuang) Co., Ltd. Dosage regimen of paliperidone palmitate extended-release injectable suspension
EP4025188B1 (en) * 2020-11-30 2024-01-10 Janssen Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
PL4005555T3 (pl) 2020-11-30 2024-09-02 Janssen Pharmaceutica Nv Sposoby zapewniania ponownego zawieszenia preparatów palmitynianu paliperydonu
SI4025187T1 (sl) 2020-11-30 2024-03-29 Janssen Pharmaceutica Nv Režimi odmerjanja, povezani s formulacijami paliperidona za injiciranje s podaljšanim sproščanjem
CN116528836A (zh) 2020-11-30 2023-08-01 詹森药业有限公司 与延长释放帕潘立酮可注射制剂相关的给药方案
MX2024002215A (es) 2021-08-20 2024-05-10 Janssen Pharmaceutica Nv Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada.
CA3230291A1 (en) * 2021-08-30 2023-03-09 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
KR102869809B1 (ko) 2023-11-21 2025-10-13 주식회사 엘지에너지솔루션 양극 및 이를 포함하는 전고체 전지
CN121914111A (zh) * 2026-03-27 2026-04-24 济南大学 一种小粒度棕榈酸帕利哌酮的结晶工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
CN101163702B (zh) 2005-04-25 2011-09-07 詹森药业有限公司 制备无菌的3-[2-[4-(6-氟-1,2-苯并异唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮棕榈酸酯的方法
CA2655335C (en) * 2007-12-19 2016-09-06 Janssen Pharmaceutica N.V. Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same
US8758780B2 (en) * 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
AU2010313290A1 (en) * 2009-10-30 2012-05-17 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
SI2529757T1 (sl) * 2011-05-31 2014-05-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija paliperidon implantata
DK3744326T3 (da) 2015-04-07 2024-02-05 Janssen Pharmaceutica Nv Doseringsregime for glemte doser til langtidsvirkende injicerbare paliperidonestere

Also Published As

Publication number Publication date
AU2022221405A1 (en) 2022-09-15
KR20230162162A (ko) 2023-11-28
NZ735952A (en) 2022-02-25
EA201792209A1 (ru) 2018-02-28
MA41917B1 (fr) 2020-07-29
JP7228503B2 (ja) 2023-02-24
AU2016244801B2 (en) 2020-06-25
PL3744326T3 (pl) 2024-03-25
MD3744326T2 (ro) 2024-05-31
AU2020239611B2 (en) 2022-07-21
EP3744326B1 (en) 2023-12-06
NZ758246A (en) 2024-05-31
TWI694825B (zh) 2020-06-01
MD3280416T2 (ro) 2020-10-31
HUE049485T2 (hu) 2020-09-28
IL254669B2 (en) 2024-05-01
EA037185B1 (ru) 2021-02-17
WO2016164218A1 (en) 2016-10-13
IL324059A (en) 2025-12-01
IL309340A (en) 2024-02-01
KR102755145B1 (ko) 2025-01-14
IL254669B1 (en) 2024-01-01
RS65024B1 (sr) 2024-01-31
HRP20201027T1 (hr) 2020-12-11
JP2018510894A (ja) 2018-04-19
JP2021130680A (ja) 2021-09-09
CY1123203T1 (el) 2021-10-29
ES2802299T3 (es) 2021-01-18
US20170281629A1 (en) 2017-10-05
AU2022221405B2 (en) 2024-08-01
TW201642863A (zh) 2016-12-16
EP3744326A1 (en) 2020-12-02
SI3744326T1 (sl) 2024-02-29
EP3280416A4 (en) 2019-01-23
AU2020239611A1 (en) 2020-10-15
UA118732C2 (uk) 2019-02-25
AU2016244801A1 (en) 2017-10-05
KR20250013293A (ko) 2025-01-31
JP7422277B2 (ja) 2024-01-26
CA3088401A1 (en) 2016-10-07
CA2925908C (en) 2020-09-01
BR112017021383A2 (pt) 2018-07-03
LT3280416T (lt) 2020-06-25
SI3280416T1 (sl) 2020-07-31
EP3280416B1 (en) 2020-04-22
ES2967585T3 (es) 2024-05-03
EP3280416A1 (en) 2018-02-14
HRP20240022T1 (hr) 2024-03-29
DK3744326T3 (da) 2024-02-05
IL309340B1 (en) 2026-01-01
DK3280416T3 (da) 2020-05-11
KR20170134583A (ko) 2017-12-06
PT3280416T (pt) 2020-06-30
EP4349323A2 (en) 2024-04-10
CA2925908A1 (en) 2016-10-07
IL254669A0 (en) 2017-11-30
RS60510B1 (sr) 2020-08-31
AU2024227790A1 (en) 2024-11-21
PL3280416T3 (pl) 2020-12-14
SMT202300478T1 (it) 2024-01-10
SMT202000351T1 (it) 2020-09-10
EP4349323A3 (en) 2024-06-12
FI3744326T3 (fi) 2024-02-02
JP2020090498A (ja) 2020-06-11
KR102606678B1 (ko) 2023-11-24
HK1249047A1 (en) 2018-10-26
LT3744326T (lt) 2023-12-27
HUE065435T2 (hu) 2024-05-28
US10143693B2 (en) 2018-12-04
PT3744326T (pt) 2024-01-15

Similar Documents

Publication Publication Date Title
JP7422277B2 (ja) 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン
JP7792959B2 (ja) 持続放出パリペリドン注射可能製剤に関連する投与レジメン
JP7792409B2 (ja) 持続放出パリペリドン注射可能製剤に関連する投与レジメン
JP2023551009A (ja) 持続放出パリペリドン注射可能製剤に関連する投与レジメン
JP2024532195A (ja) 持続放出パリペリドン注射可能製剤に関連する投与レジメン
HK40110149A (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
HK40044495A (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
HK40044495B (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
HK1249047B (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190319

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20190822

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20190903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200325

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200609

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200701

R150 Certificate of patent or registration of utility model

Ref document number: 6728221

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250